This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective was to evaluate the cost-effectiveness of two national cervical screening programmes in Hungary.
Interventions
Two programmes were evaluated in the study. Scenario one was screening by cytology and colposcopy in outpatient services by gynaecologist with active support (mass media, letters, information leaflets and local leaders and general practitioners). Scenario two was pap smear performed by trained public health nurses locally in the offices of general practitioners (colposcopic examination not offered). These interventions were compared to no screening.
Location/setting
Hungary/Primary and outpatient care.
Methods

Analytical approach:
A decision analytic Markov model was used to assess costs and outcomes associated with the interventions. The model had been previously published but was not used in its entirety; only the core disease progression component of the model was used (see Other Publications of Related Interest). The model estimated the lifespan of women on the basis of participation in one of the screening programmes. The time horizon was 20 years. The economic analysis was reported to adopt the perspective of the public healthcare payer.
Effectiveness data:
Clinical and effectiveness data were derived from previously published studies. Transition probabilities were calculated on the basis of incidence. The incidence rate was assumed to be constant. Prevalence data of different stages was estimated from three studies. The main effectiveness measures used in the model were probability of detecting cervical cancer at different disease stages. These estimates were derived from previously published studies.
Monetary benefit and utility valuations:
Age-specific utility estimates in the general population were derived from the Hungarian National Health Survey in 2000 and from previously published studies. Weights for newly diagnosed cancers at different stages were derived from the original published modelling study undertaken in USA (see Other Publications of Related Interest). Weights for undiagnosed and treated cancer were based on expert opinion.
Measure of benefit:
The summary measure of benefit was quality-adjusted life-years (QALYs) gained. Benefits could be generated over a 20-year time period. Future benefits were discounted using an annual rate of 5%.
